Skip to main content

Diabetes Remission Increased With Dapagliflozin Plus Calorie Restriction

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 27, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, Jan. 27, 2025 -- For patients with overweight or obesity and type 2 diabetes, dapagliflozin plus regular calorie restriction is associated with a significantly higher rate of remission of diabetes compared with calorie restriction alone, according to a study published online Jan. 22 in The BMJ.

Yuejun Liu, from Fudan University in Shanghai, and colleagues conducted a multicenter, double-blind randomized trial in 16 centers in China from June 12, 2020, to Jan. 31, 2023, involving 328 patients with type 2 diabetes aged 20 to 70 years, with body mass index >25 kg/m2 and diabetes duration of less than six years. Patients were randomly assigned to calorie restriction with dapagliflozin 10 mg/day or placebo.

The researchers found that diabetes remission was achieved in 44 and 28 percent of patients in the dapagliflozin and placebo groups, respectively, over 12 months (risk ratio, 1.56), meeting the predefined primary end point. Significantly greater changes in body weight (difference, −1.3 kg) and homoeostasis model assessment of insulin resistance (difference, −0.8) were seen in the dapagliflozin versus placebo group. Likewise, compared with the placebo group, significantly more improvement was seen in body fat, systolic blood pressure, and metabolic risk factors in the dapagliflozin group. The occurrence of adverse events did not differ between the groups.

"Our findings provide an alternative and more practical strategy than intensive weight management to achieve remission for patients with early type 2 diabetes," the authors write.

The study was partially funded by AstraZeneca, the manufacturer of dapagliflozin.

Abstract/Full Text

Editorial

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death

WEDNESDAY, May 28, 2025 -- For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related...

Post-Kidney Transplant Adverse Outcomes Increased With BMI-BSA Obesity

TUESDAY, May 27, 2025 -- Combined body mass index (BMI)-body surface area (BSA) obesity is associated with an increased risk for post-kidney transplant (KT) adverse outcomes...

Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss

FRIDAY, May 23, 2025 -- Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.